Immunotherapy using combined anti-PD-1 and anti-CTLA-4 in the field of NETs has been investigated in two different studies, CA209-538 and DART SWOG 1609, both enrolling patients with metastatic rare cancers. This evidence concerns the gene PDCD1 and cancer.